Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months...
Saved in:
Published in | Journal of neuroimmunology Vol. 180; no. 1; pp. 63 - 70 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.11.2006
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!